Harvard Apparatus Regenerative Tech Inc (HRGN)

$1.88 +0.01 (0.54%)
Market Cap 29.77M
Revenue (ttm) 430,000.00
Net Income (ttm) -7.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,797.67%
Debt to Equity Ratio 0.00
Volume 1,004
Avg Vol 1,068
Day's Range N/A - N/A
Shares Out 15.92M
Stochastic %K 29%
Beta -0.63
Analysts Strong Buy
Price Target N/A

Company Profile

Harvard Apparatus Regenerative Technology Inc., a clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects. Its lead product candidate is Cellspan Esophageal Implant for the treatment of severe esophageal disease. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs; and product cand...

Industry: Biotechnology
Sector: Healthcare
Phone: 774 233 7300
Website: hregen.com
Address:
84 October Hill Road, Suite 11, Holliston, United States
AdrianAnswer
AdrianAnswer Jun. 29 at 10:18 AM
$HRGN They are supposed to report results in January
0 · Reply
d_risk
d_risk Apr. 1 at 7:46 PM
$HRGN - Harvard Apparatus Regenerative Technology, Inc. - 10K - Updated Risk Factors HRGN's 2025 10-K Risk Factors highlight new concerns about going concern doubts, limited operating history, key personnel retention, collaborator commitment, ethical issues with cell tech, and cybersecurity threats. Expanded risks include regulatory challenges, liability exposure, and international operations. Stock market volatility and compliance costs also pose significant risks. #GoingConcern #StockMarketVolatility #InternationalOperations #RegulatoryChallenges #Cybersecurity 🟢 Added 🟠 Removed https://d-risk.ai/HRGN/10-K/2025-03-31
0 · Reply
BSTG2016
BSTG2016 Jan. 29 at 9:12 PM
$HRGN - A while ago, someone mentioned about a possible trial update from the company in January, 2025. Has anyone seen any sort of company release/ filing?
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jan. 2 at 4:05 PM
$HRGN CEO purchased 2,299 shares at $2.87 for a total of $6,598. He Junli now owns 262,000 shares. https://ceo-buys.com
0 · Reply
Leo72
Leo72 Dec. 12 at 7:43 PM
$HRGN
0 · Reply
AdrianAnswer
AdrianAnswer Nov. 22 at 11:31 AM
$HRGN Dropping 10K on them Monday. They have numerous Chineses investors. Their management team and connection to Chinese Hospital Capital Institute of Pediatrics in Beijing China is extra special. They are working with Maya Clinic in the U.S.! Watch their stock price after their announcement in January or sooner!!
0 · Reply
AdrianAnswer
AdrianAnswer Nov. 22 at 11:22 AM
$HRGN They are suppose to announce results of their clinical 1 and 2 January of 2025. Get end before they shoot up. Show your friends all the videos and their product. They have been doing this since 2014!
3 · Reply
Shlobby
Shlobby Nov. 13 at 9:48 PM
$HRGN got busy and forgot about this one today damn nice close
1 · Reply
Leo72
Leo72 Oct. 9 at 2:46 PM
$HRGN
1 · Reply
AdrianAnswer
AdrianAnswer Sep. 25 at 11:38 AM
$HRGN Their Clinical trials will be completed in January 2025. I liked on the clinical trials website and it has not been updated since June 2024. They just hired two new business directors and got 5 million funding to help finish trials. Do the math and buy before the price 10 fold.
0 · Reply
Latest News on HRGN
No data available.
AdrianAnswer
AdrianAnswer Jun. 29 at 10:18 AM
$HRGN They are supposed to report results in January
0 · Reply
d_risk
d_risk Apr. 1 at 7:46 PM
$HRGN - Harvard Apparatus Regenerative Technology, Inc. - 10K - Updated Risk Factors HRGN's 2025 10-K Risk Factors highlight new concerns about going concern doubts, limited operating history, key personnel retention, collaborator commitment, ethical issues with cell tech, and cybersecurity threats. Expanded risks include regulatory challenges, liability exposure, and international operations. Stock market volatility and compliance costs also pose significant risks. #GoingConcern #StockMarketVolatility #InternationalOperations #RegulatoryChallenges #Cybersecurity 🟢 Added 🟠 Removed https://d-risk.ai/HRGN/10-K/2025-03-31
0 · Reply
BSTG2016
BSTG2016 Jan. 29 at 9:12 PM
$HRGN - A while ago, someone mentioned about a possible trial update from the company in January, 2025. Has anyone seen any sort of company release/ filing?
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jan. 2 at 4:05 PM
$HRGN CEO purchased 2,299 shares at $2.87 for a total of $6,598. He Junli now owns 262,000 shares. https://ceo-buys.com
0 · Reply
Leo72
Leo72 Dec. 12 at 7:43 PM
$HRGN
0 · Reply
AdrianAnswer
AdrianAnswer Nov. 22 at 11:31 AM
$HRGN Dropping 10K on them Monday. They have numerous Chineses investors. Their management team and connection to Chinese Hospital Capital Institute of Pediatrics in Beijing China is extra special. They are working with Maya Clinic in the U.S.! Watch their stock price after their announcement in January or sooner!!
0 · Reply
AdrianAnswer
AdrianAnswer Nov. 22 at 11:22 AM
$HRGN They are suppose to announce results of their clinical 1 and 2 January of 2025. Get end before they shoot up. Show your friends all the videos and their product. They have been doing this since 2014!
3 · Reply
Shlobby
Shlobby Nov. 13 at 9:48 PM
$HRGN got busy and forgot about this one today damn nice close
1 · Reply
Leo72
Leo72 Oct. 9 at 2:46 PM
$HRGN
1 · Reply
AdrianAnswer
AdrianAnswer Sep. 25 at 11:38 AM
$HRGN Their Clinical trials will be completed in January 2025. I liked on the clinical trials website and it has not been updated since June 2024. They just hired two new business directors and got 5 million funding to help finish trials. Do the math and buy before the price 10 fold.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Sep. 12 at 9:30 PM
$HRGN CEO purchased 5,101 shares at $3.37 for a total of $17,190. He Junli now owns 259,701 shares. https://ceo-buys.com
0 · Reply
insiderbuyingselling
insiderbuyingselling Sep. 12 at 7:45 PM
$HRGN new insider buying: 5101 shares. http://insiderbuyingselling.com/?t=HRGN
0 · Reply
AdrianAnswer
AdrianAnswer Sep. 12 at 8:37 AM
$HRGN Harvard previously known as Biostsge stated on the Clinical Trials website that Jan 2025 their study of the regeneration of a small section esophagus would be completed. They are holding this trial currently and I believe the recent hiring of a new board of director speaks to positive results and numerous catalyst in near future so BUY, BUY, Buy!
0 · Reply
AlphaTuna
AlphaTuna Jul. 17 at 10:40 PM
Lowest Volume Rated General Stocks Per 7/17/2024’s Close: 1 -$FISK 2 – $SGLY 3 – $ELLO 4 – $HRGN 5 – $FGFH 6 – $FDVA 7 – $AAUKF 8 – $BCTF 9 – $GSIW 10 – $CVII https://optimizedvalue.xyz/daily-voltech-stock-etf-volume-technical-ratings-7-17-2024/
1 · Reply
insiderbuyingselling
insiderbuyingselling Jul. 2 at 4:09 PM
$HRGN new insider buying: 1600 shares. http://insiderbuyingselling.com/?t=HRGN
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Jan. 3 at 6:50 PM
$HRGN CEO purchased 2,700 shares at $4.76 for a total of $12,852. He Junli now owns 253,000 shares. https://ceo-buys.com
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 19 at 12:35 AM
$HRGN CEO purchased 900 shares at $4.92 for a total of $4,428. He Junli now owns 250,300 shares. https://ceo-buys.com
0 · Reply
Stock_Titan
Stock_Titan Dec. 18 at 2:00 PM
$HRGN Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy Article Available on StockTitan Website.
0 · Reply
CEOBuysDisclosures
CEOBuysDisclosures Dec. 11 at 9:10 PM
$HRGN CEO purchased 1,500 shares at $5.07 for a total of $7,605. He Junli now owns 249,400 shares. https://ceo-buys.com
0 · Reply